

## EXPLORING NOVEL MATERIALS AND TECHNIQUES FOR ENHANCED SKIN PERMEATION OF CINNARIZINE (CNZ) IN TRANSDERMAL PATCH DESIGN

Archana khanduji Gaikwad

Research scholar

Dr Masood Ahmed Siddiqui

Professor

Department of Pharmacy

Sun Rise University, Alwar

**DECLARATION:** I AS AN AUTHOR OF THIS PAPER /ARTICLE, HERE BY DECLARE THAT THE PAPER SUBMITTED BY ME FOR PUBLICATION IN THE JOURNAL IS COMPLETELY MY OWN GENUINE PAPER. IF ANY ISSUE REGARDING COPYRIGHT/PATENT/ OTHER REAL AUTHOR ARISES, THE PUBLISHER WILL NOT BE LEGALLY RESPONSIBLE. IF ANY OF SUCH MATTERS OCCUR PUBLISHER MAY REMOVE MY CONTENT FROM THE JOURNAL WEBSITE. FOR THE REASON OF CONTENT AMENDMENT/OR ANY TECHNICAL ISSUE WITH NO VISIBILITY ON WEBSITE/UPDATES, I HAVE RESUBMITTED THIS PAPER FOR THE PUBLICATION. FOR ANY PUBLICATION MATTERS OR ANY INFORMATION INTENTIONALLY HIDDEN BY ME OR OTHERWISE, I SHALL BE LEGALLY RESPONSIBLE. (COMPLETE DECLARATION OF THE AUTHOR AT THE LAST PAGE OF THIS PAPER/ARTICLE)

### Abstract

*In contrast with additional conventional ways, for example, oral or injectable, the transdermal course of organization offers various advantages for the treatment of different sicknesses and restorative purposes. The skin likewise fills in as a repository, permitting the medication to be conveyed over longer timeframes in a supported manner. Because of the various areas for assimilation and the chance of keeping away from fundamental antagonistic impacts, it decreases poisonousness and neighborhood touchiness. Nonetheless, the transdermal method of conveyance for some prescriptions is obliged on the grounds that it can direct a tiny number of drugs at a down to earth rate. The layer corneum of the skin fills in as a proficient obstruction, limiting the entrance of most prescriptions and making it trying for them to go through the skin. The infiltration of meds over this obstruction can, luckily, be impressively worked on by different painless strategies. As a valuable and charming other option, the utilization of nanocarriers to widen the determination of meds accessible for transdermal conveyance has created. Through the layer corneum, both lipophilic and hydrophilic prescriptions can be controlled, with the potential for neighborhood or fundamental impacts to treat various problems. This survey has inspected a few nanocarriers used*

*for transdermal medication organization, for example, nanoparticles, ectosomes, dendrimers, liposomes, and so on, as well as the construction of the skin and its principal hindrances to transdermal medication conveyance. For enhancing the therapeutic efficacy of transdermal medications, some recent instances of the coupling of nanocarrier with physical techniques, including iontophoresis, ultrasound, laser, and microneedles, have also been discussed. At the finish of this distribution, constraints and expected utilizations of nanocarriers for transdermal drug conveyance have been framed.*

**Keywords:** Drug Delivery, Novel Drug Delivery System, Transdermal.


---

## 1. INTRODUCTION

Most of little particle drugs are regularly regulated orally, with the parenteral and oral courses being the most incessant. Pre-set dosages, versatility, and patient self-organization are advantages of the oral course. Thus, regulating drugs orally is as yet the most pragmatic strategy. Nonetheless, because of quick stomach breakdown and size-limited transport across the epithelium, most of restorative peptides or proteins are not controlled orally. In this manner, giving macromolecules basically through infusion has a few disadvantages, including the requirement for organization by an expert director, the nosy person of infusions summoning torment, and diminished patient acknowledgment/consistence. It's a good idea that cutting edge drug organization strategies, including transdermal medication conveyance, can defeat the inborn limitations of the customary courses of medicine conveyance. The centralization of the medication at the site of activity, which thus relies upon the portion structure and the level of medication retention at the site of activity, decides the pharmacological reaction of a medication, including both the ideal restorative effect and the unfortunate incidental effect. Conventional medication organization strategies have included tablets and infusions; in any case, new methodologies are acquiring prevalence. Transdermal is an exceptionally viable substitute conveyance strategy. A run of the mill grown-up's skin has a surface area of around  $3\text{ m}^2$ , and it gets around 34% of the blood that courses through the body. It is expected to grasp the skin to ship a medication into the body through the transdermal layer of skin.

## 1.2. Skin physiology and life systems:

At the finish of this distribution, constraints and expected utilizations of nanocarriers for transdermal drug conveyance have been framed.



**Figure 1:** Skin Anatomy

- **Layers of the Skin**

Depending on cell size and number of cell layers, the multifaceted epidermis can range in thickness from 0.8 mm on the palms and soles of the feet to 0.06 mm on the eyelids. Table 1 documents the thickness, water porosity, and diffusivity of the cuticle. It consists of the active epidermis and the outer stratum corneum.

- **The basics of skin permeation**

The skin was thought to be impervious until the 20th century, with the exception of gases. However, the investigation in the twenty-first century showed the permeability to lipid-soluble medicines. It was also acknowledged that the skin's layers are not all equally permeable, with the epidermis being less permeable than the dermis. All skepticism regarding the stratum corneum's


permeability was dispelled following a heated debate, and it was suggested utilizing isotopic tracers that the stratum corneum significantly reduces permeation.

**Table 1:** Water permeability of the stratum corneum varies regionally

Dermis and skin	Size in micrometers	Rate of permeation (mg/ cm <sup>2</sup> /hr)	Diffusivity (cm <sup>2</sup> /sec × 1010)
Abdomen	14.5	0.33	6.1
Back	16.2	0.32	5.9
Forehead	10.0	0.28	3.4
Volar forearm	13.5	0.84	12.8
Scrotum	4.5	2.56	7.4
Back of hand	48.2	0.54	31.2
Palm	401.1	1.15	534.1
Plantar	601.1	3.91	929.1

### **Transdermal medication delivery's ideal molecular characteristics**

- Sufficient lipid and water solubility is required for deeper drug penetration (1 mg/ml).
- For a therapeutic effect to be effective, the partition coefficient must be optimal.
- A medication with a low melting point (200°C) is preferred.
- The saturated solution's pH should range from 5 to 9.



**Figure 2:** A representation of the skin with many layers that depicts the steps involved in drug delivery by transdermal permeation

## 2. LITERATURE REVIEW

Nagarkar, et.al., (2020) Drugs can be applied directly to the skin using transdermal devices. The molecular weight and hydrophilicity of the molecules, however, hinder its widespread application. The use of microneedles is a more effective method of administering medication. Microneedles of varying configurations (solid, hollow, dissolving, coated) are addressed, with emphasis on their utility in certain delivery systems. Hollow microneedles give a passage into the dermis, while solid microneedles just generate microscopic holes in the skin. Coated microneedles use a drug dispersion to effectively load pharmaceuticals, and dissolving microneedles have been investigated for vaccine delivery. The methods used to create microneedles are also the subject of this investigation. Methods including laser ablation, additive manufacturing, electromechanical systems, and solvent approaches are explored. The fabrication procedure is affected by the material's composition. Fabrication using both biodegradable and inert materials is described. Metals, silicone, ceramics, synthetic and biodegradable polymers like polysaccharides, and even bamboo have all been used to create microneedles. The benefits and drawbacks of each material type vary. Silicones are simple to manufacture yet brittle, while stainless steel is biocompatible but highly corrosive.

Marto, et.al., (2016) To obtain predominant drug items, it is judicious to research possible new purposes for excipients currently authorized for use in treatments. To all the more likely disseminate lipophilic bioactive mixtures to the skin's surface, this exploration set off to make an original starch-based nanoparticulate transporter framework. Starch-based nanoparticulate item made by the emulsification-dissolvable vanishing technique had their contribution in molecule size circulation and zeta potential assessed utilizing a quality by plan procedure. Organic awareness/aggravation examinations were directed on human workers, and the best definition was chosen and totally portrayed with regards to sub-atomic collaborations (DSC and FTIR), morphology (TEM and AFM), and in vitro and in vivo natural properties.

Orasugh, et.al., (2018) As a supporting filler in biodegradable nanocomposites with various biopolymers for applications like transdermal medication conveyance, eatable bundling, and tissue platform, nanocomposites in view of bio-determined cellulose nano-fibrils are right now getting a lot of consideration. Following the arrangement blending methodology, ultrasound was utilized to help with the union of nanocomposites in light of hydroxypropyl methylcellulose and cellulose nano-fibrils. X-beam diffraction examination has been utilized to explore the translucent design of cellulose nano-fibrils. Nano-fibrillar morphological organizations were found in field emanation checking electron micrographs of cellulose. The end of lignin and hemicellulose from natural jute filaments was checked by Fourier change infrared spectroscopy of cellulose nano-fibrils. The expansion of cellulose nano-fibrils to hydroxypropyl methylcellulose films further developed their capacity modulus and elastic characteristics up to 1.00 weight percent. At a stacking of 1.00 wt% cellulose nano-fibrils, the dampness fondness of hydrophilic hydroxypropyl methylcellulose is likewise diminished. Drug discharge from the nanocomposites films has been concentrated on according to how much cellulose nano-fibrils utilized in their planning. This adaptability of cellulose nano-fibrils is anticipated to make the produced nanocomposites exceptionally valuable in the fields of bundling and transdermal medication conveyance.

Alexander, et.al., (2012) The skin is utilized as a viable course for drug organization in the transdermal medication conveyance framework (TDDS), albeit the layer corneum goes about as a significant obstruction to sedate penetrability, lessening the bioactive's remedial bioavailability.



Iontophoresis, sonophoresis, electroporation, microneedles, magnetophoretic, photomechanical waves, and electron bar light are only a portion of the TDDS improvements that are examined in this article. These turns of events and the techniques engaged with their indicated benefits for different classes of medications are inspected finally. In spite of the broad investigation of TDDS, the framework has various downsides, including eccentric medication discharge, the powerlessness to forestall burst discharge definition, and poisonousness issues. What's more, specialists have created and detailed the synergistic impact of various combinational methodologies for delivering TDDS, including synthetic iontophoresis, compound electroporation, substance ultrasound, iontophoresis-ultrasound, electroporation-iontophoresis, electroporation-ultrasound, and tension waves-synthetic substances. This exposition gives a complete outline of these issues, making it a priceless asset for ground breaking experts in the field.

### **3. TRANSDERMAL PATCHES**

Transdermal patches and skin creams are both intended for outside use. Nonetheless, transdermal medication conveyance frameworks are used for fundamental drug conveyance, while skin dermatological meds are intended for neighborhood activity. A transdermal framework is a technique for managing drug straightforwardly into the circulation system by means of the skin. The transdermal course of prescription conveyance is acquiring prominence because of the large number of drugs that can be managed by means of this strategy. Transdermal patches are being utilized for various restorative purposes, including torment the board, smoking end, coronary illness therapy, chemical substitution, and movement disorder avoidance.

- **VARIOUS KINDS OF TRANSDERMAL PATCHES**

- A) In adhesive single layer drug:**

In this formulation, the drug is contained within the adhesive layer. In addition to holding everything together, the adhesive layer is in charge of delivering the medicine to the skin. Adhesive layer protected by backing and temporary liner.

### **B) Multi -layer drug in adhesive:**

A multi-layer drug in adhesive, which works similarly to the first but features a layer of instant drug release and another layer of controlled release, both of which are sandwiched between two layers of adhesive. The release of the medicine is facilitated by the sticky coating. There is a removable liner and a permanent backing on this patch as well.

### **C) Vapor patch:**

The adhesive layer's function in this kind of patch goes beyond simply holding the several layers together. It also functions as a market, which is frequently utilized to release essential oils during decongestion. There are many other kinds of vapor patches on the market that are designed to enhance sleep quality and lessen the effects of smoking.

### **D) Reservoir system:**

In this strategy, a film that controls the stream rate is sandwiched between an impenetrable support layer and a medication repository. Just through the rate-managing film, which might possibly be microporous, does the medication discharge. The medicine can be in an answer, suspension, gel, or scattered in a strong polymer framework in the medication supply compartment. A polymeric film with an external surface that is hypoallergenic and viable with medications can be utilized.

### **E) Matrix system:**

#### **1. Drug-in-adhesive system:**

In this sort, the medication repository is made by first scattering the medicine in a cement polymer, which is then spread by dissolvable projecting (for hot-soften glues) or liquefying (for dissolvable projecting cements) on an impenetrable support layer. Unmediated tacky polymer layers are placed on top of the repository for security.

#### **2. Matrix-dispersion system:**



In this sort, a hydrophilic or lipophilic polymer lattice has a uniform conveyance of the prescription. This medication containing polymer circle is housed in a compartment produced using a medication impermeable sponsorship layer and clung to an occlusive base plate. The cement is put around the beyond the medication repository as opposed to all over to make a piece of glue edge.

#### F) Micro reservoir system:

This type of drug delivery system combines a portal delivery component with storage. The manufacturing cycle for a drug depot consists of first suspending the drug in a liquid mixture of water-soluble polymers before uniformly distributing the mixture in a lipophilic polymer to form bulk small circles supply blocked medicine. Cross-linking the polymer in situ with cross-linking specialists rapidly balances this thermodynamically unstable diffusion.




Figure 3: Skin permeability for drug absorption.

## 4. MATERIALS AND METHOD

### • Cinnarizine Standard Graph Preparation

One milligram per milliliter (mg/ml) of cinnarazine (CNZ) was synthesized by dissolving 100 milligrams of CNZ in 101 milliliters of methanol. Sodium lauryl sulfate (SLS) 0.5% phosphate buffer solution (pH 7.4) was used to dilute the standard stock solution to a final concentration of 100 g/ml. Dilutions were prepared using a 0.5% SLS-containing phosphate buffer solution at pH 7.4. Using a UV-Visible spectrophotometer set to max 250 nm, we calculated the absorbance of these titrated medication solutions. We made our own 1mg/ml cinnarazine (CNZ) stock solution in-house as a standard.

**Table 2:** CNZ dissolved in phosphate buffer (pH 7.4) with 0.5% SLS and a typical graph

Concentration (µg/ml)	250 nm Absorbance
0	0
2	0.107
4	0.224
6	0.330
8	0.451
10	0.563
12	0.676
14	0.780
16	0.865

- **Research Prior to Formulation**

One milligram of the drug was broken up in a scope of solvents and transporters including oleic corrosive, tween 80, transcutol-p, labrasol, olive oil, Stake 400, and propylene glycol.

- **Identifying the melting point**

A melting point apparatus digital melting point apparatus was used to measure the melting point of the drug by placing a little amount of the drug in a capillary tube with a closed end.

- **Analysis of drug-excipient compatibility**

The infrared spectra of Cinnarizine and the drug/polymer mixture were measured using an FTIR-spectrophotometer to look for evidence of an interaction between the two substances in the patches.

- **Transdermal patch preparation**

Utilizing a dissolvable projecting strategy, transdermal patches containing Cinnarizine were made utilizing changing centralizations of hydrophilic and hydrophobic polymers. In the wake of apportioning the right measures of every polymer, they were disintegrated in 30 ml of a dichloromethane: methanol dissolvable blend and let 6 hours to grow. Solubilized Cinnarizine in oleic acid was added, along with PEG 400 (15%w/w), and the mixture was left alone for 2 hours to let any trapped air escape before being placed to a petriplate (40cm<sup>2</sup>) and dried at room temperature. Carefully removing the formed patches, trimming them to size, and storing them in desiccators. Table 3 shows that,

**Table 3:** Transdermal Patches containing Cinnarizine: Formulation and Design

Coding for a Formula	Components (in grams)				
	Drug (mg)	HPMC E50 cps	E. E100	E.RL.100	E.RS100
F1	258	291.83	14.58	-	-
F2	258	277.22	-	14.58	-
F3	258	277.22	-	-	14.58
F4	258	277.22	29.19	-	-
F5	258	262.62	-	29.19	-
F6	258	262.62	-	-	29.19
F7	258	262.62	43.78	-	-
F8	258	248.0	-	43.78	-
F9	258	248.05	-	-	43.78
F10	258	248.05	58.37	-	-
F11	258	233.46	-	58.37	-
F12	258	233.46	-	-	58.37

F13	258	233.46	72.96	-	-
F14	258	218.87	-	72.96	-
F15	258	218.87	-	-	72.96
F16	258	218.87	83.65	-	-

- **Studies of stability**

Formulation optimization the formulation with the code F3 was the one that performed the best in short-term stability tests. Transdermal films were stored in a humidity room at 40.2 degrees Celsius and 75.5 percent relative humidity for three months, as recommended by the ICH recommendations.

- **Thickness**

Transdermal patches were sliced lengthwise, and the lengths of the resulting strips were recorded. Percent constriction was used to evaluate the length variation caused by uneven flatness.

$$\text{Percent constriction} = \frac{\text{Final length} - \text{Initial length}}{\text{Initial length}} \times 100$$

- **Moisture Content Percentage**

Three films were chosen at random and each was weighed after being stored in a desiccator with anhydrous calcium chloride for 24 hours at room temperature. The films were weighed at regular intervals until their mass remained consistent.

$$\text{Percentage moisture content} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Final weight}} \times 100$$

- **Research on moisture absorption**


The films were gauged unequivocally and placed in a desiccator containing aluminum chloride to stay aware of 79.50% RH. After 3 days, the motion pictures were taken out and checked.

$$\text{Percentage moisture uptake} = \frac{\text{Final weight} - \text{Initial weight}}{\text{Initial weight}} \times 100$$

## 5. RESULT AND DATA ANALYSIS

- **Research into the diffusion of water vapor (WVTR)**

Each patch was 4.52 square centimeters in area, and one gram of fused calcium chloride was inserted into empty, previously dried vials of the same diameter. After an accurate first weight was recorded, the vials were stored in desiccators with saturated Krebs solution or potassium chloride KCal solution to keep the relative humidity (RH) at or below 63%. After the first, second, and third days, and again after seven days, the vials were weighed again to quantify the amount of moisture transferred via the patch. g/h/cm<sup>2</sup> is the unit of measure for the water vapor transfer rate.



**Figure 4:** Phosphate buffer solution with 0.5% sodium lauryl sulfate and CNZ standard curve (max250nm).

- **Research on skin irritations**

Study participants were 10 healthy adults aged 22 to 26 (Jadhav et al., 2009). Using adhesive tape USP, a patch containing the medicine was put to the right volar forearm, and a patch without the drug was applied to the left volar forearm. After 2 days, the area under the patch was checked for signs of irritation, redness, itching, and edema.

- **Solubility tests conducted prior to formulation**

CNZ was most soluble in oleic acid, a common cooking fat. CNZ is most soluble in oleic acid, followed by other fats and oils. Propylene glycol > tween 80 > labrasol > olive oil > PEG 400 > tween 80.


- **Calculating the melting point and partition coefficient**

Cinnarizine was discovered to have a melting point of 119 degrees Celsius and a partition coefficient of 5.9.

- **Skin penetration on the abdomen**

Since CNZ is so poorly soluble in water, a release media (a phosphate buffer with a pH of 7.4 and 0.5% SLS) was employed to facilitate its dissolution. Figure 3 displays the permeability coefficient  $K_p=0.00166$  of the drug solution through the abdomen skin of rats. The flux measured was 1.666g/cm<sup>2</sup> /hr.





**Figure 5:** Abdominal skin permeability to CNZ in vitro.

## 6. CONCLUSIONS

The quantity of meds that can be conveyed transdermal would rise decisively with the advancement of skin saturation improvement innovations. The many benefits of the transdermal drug organization course over the oral organization of drugs have provoked examination into the utilization of various enhancers to defeat the skin's hindrance capability. Over numerous many years, researchers have committed a lot of significant investment to the quest for the ideal skin infiltration enhancer. Many elements should be considered for transdermal medication application to find success. Since the skin's essential jobs are in security and control, it appears to be an unrealistic objective for medicine conveyance. Numerous strong enhancers have been found; be that as it may, their belongings are commonly joined by poisonousness. Enhancers with ideal characteristics and least poisonousness can be created thanks to late advances in how we might interpret the idea of the layer corneum hindrance, the collaboration of activators with the stratum corneum and the basis of active connections that build for activators. Strong future advances in transdermal products will depend heavily on input activators.

## REFERENCES

1. Alexander, A., Dwivedi, S., Giri, T. K., Saraf, S., Saraf, S., & Tripathi, D. K. (2012). *Approaches for breaking the barriers of drug permeation through transdermal drug delivery. Journal of Controlled Release, 164(1), 26-40.*
2. Allen LV, Popovich NG, Ansel HC. *Pharmaceutical dosage form and drug delivery systems, seventh edition, Lippincott Williams and Wilkins, 2002, 263-278.*
3. Arora N, Singh K, Garg T. (2012). *Areas of nanomedicine applications. Int J Univ Pharm Life Sci 2:216–27.*
4. Al Hanbali, O. A., Khan, H. M. S., Sarfraz, M., Arafat, M., Ijaz, S., & Hameed, A. (2019). *Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica, 69(2), 197-215.*
5. Auriemma, G., Tommasino, C., Falcone, G., Esposito, T., Sardo, C., & Aquino, R. P. (2022). *Additive manufacturing strategies for personalized drug delivery systems and medical devices: fused filament fabrication and semi solid extrusion. Molecules, 27(9), 2784.*
6. Barker DJ, Bercovicz D, Servilio LC, et al. (2013). *Rat ultrasonic vocalizations demonstrate that the motivation to contextually reinstate cocaine-seeking behavior does not necessarily involve a hedonic response. Addict Biol. [Epub ahead of print]. doi: 10.1111/adb.12044*
7. Bi, Y., Xia, H., Li, L., Lee, R. J., Xie, J., Liu, Z., et al. (2019). *Liposomal Vitamin D3 as an anti-aging agent for the skin. Pharmaceutics 11:311. doi: 10.3390/pharmaceutics11070311.*
8. Carolina Oliveira Dos Santos, L., Spagnol, C. M., Guillot, A. J., Melero, A., and Corrêa, M. A. (2019). *Caffeic acid skin absorption: delivery of microparticles to hair follicles. Saudi Pharm. J. 27, 791–797. doi: 10.1016/j.jsps.2019.04.015.*
9. *Delivery Times, You can't Tech an old patch new trick or can you, an Alza Technologies publication, volume -I, Issue III, [Internate], URL: <http://www.Alza.com>.*
10. Dubey V, Mishra D, Jain NK. (2007). *Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm 67:398–405*

11. Keleb E, Sharma RK, Mosa EB, Aljahwi AZ. *Transdermal Drug Delivery System- Design and Evaluation. International Journal of Advances in Pharmaceutical Sciences* 2010; 1: 201-211.
12. Kumar JA, Pullakandam N, Prabu SL, Gopal V. *Transdermal drug delivery system: an overview. International Journal of Pharmaceutical Sciences Review and Research.* 2010; 3(2): 49-54.
13. Kim, E. J., & Choi, D. H. (2021). *Quality by design approach to the development of transdermal patch systems and regulatory perspective. Journal of Pharmaceutical Investigation*, 51(6), 669-690.
14. Marto, J., Gouveia, L. F., Gonçalves, L. M., Gaspar, D. P., Pinto, P., Carvalho, F. A., ... & Almeida, A. J. (2016). *A quality by design (QbD) approach on starch-based nanocapsules: a promising platform for topical drug delivery. Colloids and surfaces B: Biointerfaces*, 143, 177-185.
15. Nagarkar, R., Singh, M., Nguyen, H. X., & Jonnalagadda, S. (2020). *A review of recent advances in microneedle technology for transdermal drug delivery. Journal of Drug Delivery Science and Technology*, 59, 101923.
16. Orasugh, J. T., Saha, N. R., Rana, D., Sarkar, G., Mollick, M. M. R., Chattoapadhyay, A., ... & Chattopadhyay, D. (2018). *Jute cellulose nano-fibrils/hydroxypropylmethylcellulose nanocomposite: A novel material with potential for application in packaging and transdermal drug delivery system. Industrial Crops and Products*, 112, 633-643.
17. Phatale, V., Vaiphei, K. K., Jha, S., Patil, D., Agrawal, M., & Alexander, A. (2022). *Overcoming skin barriers through advanced transdermal drug delivery approaches. Journal of controlled release*, 351, 361-380.
18. Wilkosz MF. *Transdermal Drug Delivery, Part I: CURRENT STATUS U. S. Pharmacist*, 2003, 28, [Internate] URL: [http://U\\_S\\_Pharmacist.htm](http://U_S_Pharmacist.htm).
19. Ramadan, E., Borg, T., Abdelghani, G. M., & Saleh, N. M. (2018). *Design and in vivo pharmacokinetic study of a newly developed lamivudine transdermal patch. Future Journal of Pharmaceutical Sciences*, 4(2), 166-174.

20. Cilurzo, F., Musazzi, U. M., Franzé, S., Fedele, G., & Minghetti, P. (2018). *Design of in vitro skin permeation studies according to the EMA guideline on quality of transdermal patches. European Journal of Pharmaceutical Sciences, 125*, 86-92.
21. SANTI, T. D., SIREGAR, T. N., SUTRIANA, A., ANDINI, R., & CANDRA, A. (2022). *Phytochemical test and optimization of transdermal patches of Carica papaya extract: Formulation design of candidate drug for wound healing. Biodiversitas Journal of Biological Diversity, 23*(6).
22. Peterson, T. A., Wick, S. M., & Ko, C. (2020). *Design, development, manufacturing, and testing of transdermal drug delivery systems. In Dermal Drug Delivery (pp. 121-162). CRC Press.*
23. Saal, W., Ross, A., Wytenbach, N., Alsenz, J., & Kuentz, M. (2018). *Unexpected solubility enhancement of drug bases in the presence of a dimethylaminoethyl methacrylate copolymer. Molecular pharmaceutics, 15*(1), 186-192.
24. de Melo Mendes, V., Tempone, A. G., & Borborema, S. E. T. (2019). *Antileishmanial activity of H1-antihistamine drugs and cellular alterations in Leishmania (L.) infantum. Acta tropica, 195*, 6-14.
25. Auriemma, G., Tommasino, C., Falcone, G., Esposito, T., Sardo, C., & Aquino, R. P. (2022). *Additive manufacturing strategies for personalized drug delivery systems and medical devices: fused filament fabrication and semi solid extrusion. Molecules, 27*(9), 2784.
26. Drakakis, G., Cortés-Ciriano, I., Alexander-Dann, B., & Bender, A. (2019). *Elucidating compound mechanism of action and predicting cytotoxicity using machine learning approaches, taking prediction confidence into account. Current protocols in chemical biology, 11*(3), e73.
27. Rao, M. R., Sonavane, V., Kulkarni, S., Magar, M., Zope, A., & Karanjkar, P. (2019). *Design of transdermal patch of ketoprofen by full factorial design for treatment of rheumatoid arthritis. Journal of Drug Delivery and Therapeutics, 9*(2), 197-205.

28. Hashmat, D., Shoaib, M. H., Ali, F. R., & Siddiqui, F. (2020). *Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers. Plos one, 15(2), e0228908.*
29. Bird, D., & Ravindra, N. M. (2020). *Transdermal drug delivery and patches—An overview. Medical Devices & Sensors, 3(6), e10069.*
30. Chauhan, M. K., & Sharma, P. K. (2019). *Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. Chemistry and physics of lipids, 224, 104794.*

### Author's Declaration

I as an author of the above research paper/article, hereby, declare that the content of this paper is prepared by me and if any person having copyright issue or patent or anything otherwise related to the content, I shall always be legally responsible for any issue. For the reason of invisibility of my research paper on the website/amendments/updates, I have resubmitted my paper for publication on the same date. If any data or information given by me is not correct, I shall always be legally responsible. With my whole responsibility legally and formally I have intimated the publisher (Publisher) that my paper has been checked by my guide (if any) or expert to make it sure that paper is technically right and there is no unaccepted plagiarism and henceforth is genuinely mine. If any issue arises related to Plagiarism/Guide Name /Educational Qualification /Designation /Address of my university /college /institution /Structure or Formatting/ Resubmission / Submission /Copyright / Patent/Submission for any higher degree or Job/Primary Data/Secondary Data Issues. I will be solely/entirely responsible for any legal issues. I have been informed that the most of the data from the website is invisible or shuffled or vanished from the data base due to some technical fault or hacking and therefore the process of resubmission is there for the scholars/students who find trouble in getting their paper on the website. At the time of resubmission of my paper I take all the legal and formal responsibilities, If I hide or do not submit the copy of my original documents (Aadhar/Driving License/Any Identity Proof and Photo) in spite of demand from the publisher then my paper may be rejected or removed from the website anytime and may not be considered for verification. I accept the fact that as the content of this paper and the resubmission legal responsibilities and reasons are only mine then the Publisher (Airo International Journal/Airo National Research Journal) is never responsible. I also declare that if publisher finds any complication or error or anything hidden or implemented otherwise, my paper may be removed from the website or the watermark of remark/actuality may be mentioned on my paper. Even if anything is found illegal publisher may also take legal action against me

**Archana khanduji Gaikwad**  
**Dr Masood Ahmed Siddiqui**

\*\*\*\*\*